http://purl.org/np/RAvw8F2rV_yfYooruBvDAlNEOhbPf_t199nf4lj22XFXE#Head http://purl.org/np/RAvw8F2rV_yfYooruBvDAlNEOhbPf_t199nf4lj22XFXE http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAvw8F2rV_yfYooruBvDAlNEOhbPf_t199nf4lj22XFXE#assertion http://purl.org/np/RAvw8F2rV_yfYooruBvDAlNEOhbPf_t199nf4lj22XFXE http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAvw8F2rV_yfYooruBvDAlNEOhbPf_t199nf4lj22XFXE#provenance http://purl.org/np/RAvw8F2rV_yfYooruBvDAlNEOhbPf_t199nf4lj22XFXE http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAvw8F2rV_yfYooruBvDAlNEOhbPf_t199nf4lj22XFXE#pubinfo http://purl.org/np/RAvw8F2rV_yfYooruBvDAlNEOhbPf_t199nf4lj22XFXE http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAvw8F2rV_yfYooruBvDAlNEOhbPf_t199nf4lj22XFXE#assertion http://purl.obolibrary.org/obo/DOID_1920 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAvw8F2rV_yfYooruBvDAlNEOhbPf_t199nf4lj22XFXE#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_1920 http://purl.org/np/RAvw8F2rV_yfYooruBvDAlNEOhbPf_t199nf4lj22XFXE#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAvw8F2rV_yfYooruBvDAlNEOhbPf_t199nf4lj22XFXE#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB11560 http://purl.org/np/RAvw8F2rV_yfYooruBvDAlNEOhbPf_t199nf4lj22XFXE#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAvw8F2rV_yfYooruBvDAlNEOhbPf_t199nf4lj22XFXE#association http://www.w3.org/2000/01/rdf-schema#label zurampic is indicated in combination with a xanthine oxidase inhibitor for the treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a xanthine oxidase inhibitor alone s ee clinical studies 14 zurampic is a urat1 inhibitor indicated in combination with a xanthine oxidase inhibitor for the treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a xanthine oxidase inhibitor alone 1 limitations of use zurampic is not recommended for the treatment of asymptomatic hyperuricemia 1 1 zurampic should not be used as monotherapy 1 1 5 1 zurampic is not recommended for the treatment of asymptomatic hyperuricemia zurampic should not be used as monotherapy see warnings and precautions 5 1 http://purl.org/np/RAvw8F2rV_yfYooruBvDAlNEOhbPf_t199nf4lj22XFXE#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RAvw8F2rV_yfYooruBvDAlNEOhbPf_t199nf4lj22XFXE#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAvw8F2rV_yfYooruBvDAlNEOhbPf_t199nf4lj22XFXE#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB11560 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAvw8F2rV_yfYooruBvDAlNEOhbPf_t199nf4lj22XFXE#provenance http://purl.org/np/RAvw8F2rV_yfYooruBvDAlNEOhbPf_t199nf4lj22XFXE#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAvw8F2rV_yfYooruBvDAlNEOhbPf_t199nf4lj22XFXE#pubinfo http://purl.org/np/RAvw8F2rV_yfYooruBvDAlNEOhbPf_t199nf4lj22XFXE#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAvw8F2rV_yfYooruBvDAlNEOhbPf_t199nf4lj22XFXE#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAvw8F2rV_yfYooruBvDAlNEOhbPf_t199nf4lj22XFXE#sig http://purl.org/nanopub/x/hasSignature TCktFV5r6rSCbj7Zv1K4VQXaDLk9+3W9CEgmJZqsbGrzf6H5nlQxCfPWrGn1f38drns6pgwm3d7m8OXU/8zOk1+SpSTBr6Gdl1nACEq7QSnCi60IyjVLySEkHmH4bU4tb4kdapUVyA9Wk81iRxMWXRSmdeZRIQxEz/TzPTuTbm8= http://purl.org/np/RAvw8F2rV_yfYooruBvDAlNEOhbPf_t199nf4lj22XFXE#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAvw8F2rV_yfYooruBvDAlNEOhbPf_t199nf4lj22XFXE http://purl.org/np/RAvw8F2rV_yfYooruBvDAlNEOhbPf_t199nf4lj22XFXE http://purl.org/dc/terms/created 2021-06-12T12:52:49.021+02:00 http://purl.org/np/RAvw8F2rV_yfYooruBvDAlNEOhbPf_t199nf4lj22XFXE http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAvw8F2rV_yfYooruBvDAlNEOhbPf_t199nf4lj22XFXE https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAvw8F2rV_yfYooruBvDAlNEOhbPf_t199nf4lj22XFXE https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAvw8F2rV_yfYooruBvDAlNEOhbPf_t199nf4lj22XFXE https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs